SAB Biotherapeutics, Inc.
https://sabbiotherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From SAB Biotherapeutics, Inc.
Sanofi’s Tzield Delays Children’s Type 1 Diabetes Progression, But Falls Short On Clinical Impact
Sanofi paid $2.9bn for Tzield and its developer Provention earlier this year, but a mixed readout in its key Phase III study will raise doubts among analysts about its long-term prospects in later-stage patients.
Synairgen’s Hopes For Inhaled COVID-19 Therapy Dwindle
The company is running out of chances for its inhaled interferon therapy after a Phase III study failed to show benefits for hospitalized COVID-19 patients.
SPAC Mergers Take Biopharmas Public, But Valuations Often Sag Post-Closing
Merging with a special purpose acquisition corporation is a viable funding tool, but it may not be the best choice for drug developers far from key milestones.
Finance Watch: Two New VC Funds Raise $955m To Back Life Science Companies
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice